A strategic and collaborative leader with an entrepreneurial focus and track record of success. Demonstrated leadership, strategic, transactional, and team-building skills creating value for biopharma companies. Operational expertise selecting product portfolios and setting development strategy, interfacing with investors and partners for fund-raising, business development and M&A, and leading high performing teams to execute. • Development experience with small molecules, biologics, peptides, and drug delivery technologies across numerous therapeutic areas• Executive leadership and fund-raising, gaining access to nearly $150 million in financing • Pharma and biotech product and technology partnerships• Buy-side and sell-side deal expertise, multiple geographies• M&A transactions, including 2 go-public deals• Significant expertise in rare diseasesI particularly enjoy the art of turning science into products with the potential to transform the standard of care, and leading teams to make those products a business that can offer hope patients deserve and the return investors require.
-
Entrepreneur In ResidenceFormation BioRaleigh, Nc, Us -
Co-Founder, Chief Executive Officer & DirectorAceragen 2021 - 2024Durham, North Carolina, UsClinical-stage therapeutics company focused on late-stage rare disease portfolio in pulmonary and rheumatology. Devised and executed corporate strategy resulting in funding, product and merger transactions, including gaining a public listing via reverse merger. Led senior team in building an amazing 30-person development and operations team. Pre-Nasdaq, company’s access to funding was ~$95 million. -
Board MemberBelhaven Biopharma Jan 2022 - Dec 2023Belhaven is a clinical-stage drug development company advancing novel products using nasal delivery. -
Entrepreneur In ResidenceNorth Carolina Biotechnology Center 2018 - 2022Research Triangle Park, Nc, UsAssisted NCBC staff in creating EIR program to add strength to investment team and provide strategic guidance to therapeutic and drug development companies. Rejoined team in 2024. -
Co-Founder, Chief Executive Officer & DirectorSpyryx Biosciences 2013 - 2018Durham, Nc, UsClinical-stage biotech company launched from UNC-Chapel Hill to develop ENaC modulators as novel therapies for lung complications associated with cystic fibrosis. Funded by Canaan, Hatteras, and 5AM, with an additional development award from the CF Foundation. -
Vice President, Corporate DevelopmentSynageva Biopharma Corp. 2009 - 2013Lexington, Massachusetts, UsTherapeutic protein company focused on lysosomal storage disorders and other rare/ultra-rare diseases. Lead product, Kanuma, approved for lysosomal acid lipase deficiency (LALD) in US and EU. Led corporate and business development function sourcing deals and supporting product development portfolio. Major partnering transactions with Mitsubishi Tanabe; played a key role in executing reverse merger with Trimeris. -
Vice President, Business DevelopmentJavelin Pharmaceuticals, Inc. Apr 2008 - Sep 2009Cambridge, Massachusetts, UsPharmaceutical company developing and commercializing products for post-operative pain and cancer-breakthrough pain. Led business development and strategic partnering function, major EU product transaction with Therabel. -
Director, Business DevelopmentEurand Pharma 2003 - 2008Specialty pharma commercializing oral drug delivery platform. Senior member of US BD team, sourced 8 development deals in 5 years including 3 of the company's largest.
-
Director, Business DevelopmentSarnoff Corporation 2001 - 2002Us -
Licensing Product ManagerAmersham Pharmacia Biotech 1998 - 2001
-
Bioprocessing SpecialistBiowhittaker 1994 - 1998
John Taylor Education Details
-
The Wharton SchoolTechnology Management -
Clemson UniversityBiological Sciences
Frequently Asked Questions about John Taylor
What company does John Taylor work for?
John Taylor works for Formation Bio
What is John Taylor's role at the current company?
John Taylor's current role is Entrepreneur in Residence.
What schools did John Taylor attend?
John Taylor attended The Wharton School, Clemson University.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial